NEW YORK, Dec. 17, 2025 /PRNewswire/ — Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against NowRx, Inc. (“NowRx”) and certain of its officers.
This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired NowRx securities between February 1, 2022 and November 5, 2022, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site: bgandg.com/nowrx.
NowRx Case Details
The Complaint alleges that NowRx and other defendants failed to disclose:
- material, adverse facts concerning NowRx’s financial condition;
- that NowRx was on the brink of bankruptcy or insolvency;
- that NowRx had hired an investment bank to explore a sale or raise significant funds so that it could continue operations;
- that as of December 31, 2021, NowRx was itself valued by an investment bank at $3.55 per share and this $3.55 per share price was significantly less than the $10.50 per share offering price in the Company’s Series C stock offering in 2022; and
- as a result, investors in the Series C stock offering would likely lose their investment.
What’s Next for NowRx Investors?
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm’s site: bgandg.com/nowrx. or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 917-590-0911. If you suffered a loss in NowRx you have until January 23, 2026, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as lead plaintiff.
No Cost to NowRx Investors
We, Bronstein, Gewirtz & Grossman LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman, LLC for NowRx Securities Class Action?
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide. More at www.bgandg.com
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace,” said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Contact Info
Peretz Bronstein, Esq. or Nathan Miller
Bronstein, Gewirtz & Grossman, LLC
917-590-0911 | info@bgandg.com
Attorney advertising.
Prior results do not guarantee similar outcomes.
View original content to download multimedia:https://www.prnewswire.com/news-releases/bronstein-gewirtz–grossman-llc-urges-nowrx-inc-investors-to-act-class-action-filed-alleging-investor-harm-302644721.html
SOURCE Bronstein, Gewirtz & Grossman, LLC
